Publications and Press Releases. The Steering Group shall decide procedures for dissemination of publications and press releases relating to the Project
Publications and Press Releases. 6.2.4.1 The Technical Oversight Group in discussion with the Delivery Body shall decide procedures for dissemination of publications and press releases, joint or otherwise, relating to the Project.
Publications and Press Releases. Service Provider must obtain PARATEK’s approval before publicly disclosing any publication or press release relating to this Agreement or Service Provider’s performance under this Agreement.
Publications and Press Releases. 10.1. The Clinical Trial is being conducted as part of a multi-center clinical trial. In accordance with the Protocol, data from all of centers will be pooled and analyzed for publication in a final report (“Primary Publication”). NIAID agrees that the Primary Publication to be coordinated by Company may be the first publication to present the pooled results from all sites conducting the clinical trial. Before either Party submits a paper or abstract for publication or otherwise intends to publicly disclose information about the clinical trial, the other Party shall be provided […***…] to review the proposed publication. The publication or other disclosure shall be delayed for up to […***…] upon written request by either Party.
10.2. Any NIAID Publications will conform to NIH publication policies. Unless requested otherwise by Company, NIAID will acknowledge Company as the source of the Test Article in any NIAID Publication resulting from the Clinical Trial.
10.3. Recognizing that employees of either Party may play an important role in the design, analysis, and interpretation of the findings of the Clinical Trial, each Party will include appropriate individuals from the other Party in the authorship of any publications resulting from the Clinical Trial, in accordance with the generally accepted customs pertaining to authorship.
10.4. NIAID will provide Company with a copy of any abstract, presentation, or manuscript prior to submission for a NIAID Publication with sufficient time for review and comment as provided in Section 10.1. NIAID agrees that, following Company review of any NIAID abstract and/or manuscript for the maximum periods of time specified above, if no comment is received by Company, NIAID will be free to publish, present the NIAID Publication. Company will maintain the proposed NIAID Publication as NIAID Confidential Information until such NIAID Publication is published. If Company requests additional time to file a patent application related to a NIAID Publication, that NIAID Publication re may be delayed for up to […***…] and up to […***…] for abstracts, upon written request by Company as necessary to preserve U.S. or foreign patent or other intellectual property rights.
10.5. Each Party will provide a copy of any proposed press release to the other Party for review and comment at least […***…] in advance of such proposed press release. Each Party agrees that, following the receiving Party’s review of a proposed press release for the maxi...
Publications and Press Releases. Neither Party shall issue any press release, publication, or any other public announcement relating to this Agreement, without obtaining the other Party’s prior written approval, provided, however, that the parties may issue a mutually agreed upon joint press release regarding this Agreement at a time to be mutually agreed upon. Once such press releases or other public announcements have been approved for disclosure by the parties, such approval will not be required again before a Party may subsequently repeat disclosure of information contained therein. Notwithstanding the foregoing, each Party shall have the right to make such disclosures as may be required by applicable laws, including applicable securities laws.
Publications and Press Releases. 10.1 Any publications based on the results of the Clinical Trial and originating from NHLBI or the Investigators will conform to the latest version of the CTSN Grants Policy on Publication and Presentation. Unless requested otherwise by the Company, the NHLBI will acknowledge the Company as the source of the Test Article in any NHLBI publication resulting from the Clinical Trial and will request that the Investigators do the same in their publications resulting from the Clinical Trial, however, NHLBI’s request will not constitute a term or condition for making or renewing a grant award to an Investigator.
10.2 Recognizing that employees of either Party may play an important role in the design, analysis, and interpretation of the findings of the Clinical Trial, each Party will include appropriate individuals from the other Party in the authorship of publications resulting from the Clinical Trial, in accordance with the generally accepted customs pertaining to authorship (as detailed in the NHLBI-approved CTSN Manual of Procedures), and NHLBI will require the Investigators to include appropriate individuals from both Parties in their publications resulting from the Clinical Trial.
10.3 Each Party will, and NHLBI will request that the Investigators provide the other Party with a copy of any abstract, manuscript or other disclosure containing data not previously reviewed by the other Party (“Publication”) prior to submission for publication with sufficient time for review and NHLBI Extramural Clinical Trial Agreement (Cooperative Agreement) CTSN DCC Protocol # CTSNLVAD02 Mesoblast – DCVS, NHLBI July 2014 comment (5 business days for abstracts, 30 calendar days for any other publication). Each Party agrees that, following the receiving Party’s review of the abstract and/or manuscript for the maximum periods of time specified above, and subject to other restrictions contained in this Agreement, the submitting Party and/or the Investigators will be free to publish, present or use any Clinical Trial data, unless Company determines during the thirty (30) day review period that the Publication contains patentable subject matter, then and at Company’s discretion, the disclosure will be postponed for an additional forty-five (45) days in order to allow for the preparation of patent applications covering said patentable subject matter. Further, each Party shall receive any comments or edits from any editorial committees post-submission in order to consider and comment ...
Publications and Press Releases a. Supplier has an interest in obtaining valid patent protection. Supplier’s employees or consultants wishing to make a publication that refers specifically to this Agreement will share with Company a copy of the proposed written publication.
b. Communications required by applicable law or the requirement or request of any securities exchange on which the Party’s securities are listed or traded, and informational marketing and website postings will not require advance approval.
Publications and Press Releases. All publications regarding Knowledge, including data, obtained under the Project shall be submitted to the Steering Committee and all Contractors at least thirty (30) calendar days prior to the submission to the publisher or the planned disclosure date; any objection concerning publications arising from the Project shall be notified by the Steering Committee or a Contractor within thirty (30) calendar days. Every Contractor involved in a publication arising from the Project has to agree on the content (abstract sufficient) and on the name and order of the authors. Publications shall be made in accordance with good academic practice. All the publications arising from the Project shall make reference to the Project title, the Contract and the appropriate funding institutions (wording to be defined at the first meeting of the SC). The obligations shown in this Article shall remain applicable for five (5) calendar years after the end of this Consortium Agreement and of the Contract. No Contractor shall have the right to publish or allow the publishing of data which constitutes another Contractor’s Knowledge, Pre-existing Know-how or confidential information, even where such data are amalgamated with such first Contractor’s Knowledge, Pre-existing Know-how or other information, document or material. Any use of such other Contractor’s data justifies, save for further remedies, objection to the publication by the Contractor concerned in accordance with the Contract. The publishing Contractor(s) must supply details of their planned Project publication by providing title, authors and an abstract to all Contractors. Any Contractor opposing such publication shall notify their opposition to the Steering Committee and the publishing Contractor(s9 within thirty (30) calendar days. Any opposition to the planned publication shall be made on justified grounds in accordance with this Consortium Agreement and the Contract. In case of opposition, the involved Contractors shall discuss how to remedy the situation, including the option of the removal of any disclosure of copyright (for example software) owned by a non publishing Contractor, and the opposing Contractor(s) shall not unreasonably continue the opposition if the agreed actions are performed following the discussion. The justified grounds of opposition can be: - Legitimate Interests of a Contractor; - Confidentiality reasons concerning for example the inclusion of the opposing Contractor's Knowledge or Pre-existing K...
Publications and Press Releases. 10.1 Any publications based on the results of the Clinical Trial and originating from NIAID or the Investigators will conform to the applicable publication policy for the Clinical Trial. Unless requested otherwise by the Company, the NIAID will acknowledge the Company as the source of the Test Article in any NIAID publication resulting from the Clinical Trial and will request that the Investigators do the same in their publications resulting from the Clinical Trial.
Publications and Press Releases. Neither Party shall issue any press release, publication, or any other public announcement relating to this Agreement, without obtaining the other Party’s prior written approval, provided, however, that the parties may issue a mutually agreed upon joint press release regarding this Agreement at a time to be mutually agreed upon. In the event a Party desires to publish in a scientific or academic journal or similar publication or to make a public presentation in the form of a seminar or lecture or the like, Confidential Information developed by such Party relating to a Licensed Product, in addition to any necessary internal reviews or approvals by such Party, such Party shall submit a copy of the proposed publication or presentation to the other Party [***] days prior to any disclosure or submission to any Third Party. The parties agree to review and evaluate the submission to determine the effect, if any, that such publication or presentation would have on the commercialization of Licensed Products, whereupon the parties may either approve, require modifications to, or disapprove the proposed publication or presentation. Neither Party shall have the right to publish or present Confidential Information of the other and shall remove the Confidential Information of the other Party from any proposed publication or presentation at the request of the other Party. Once such press releases, publications, or other public announcements have been approved for disclosure by the parties, such approval will not be required again before a Party may subsequently repeat disclosure of information contained therein. Notwithstanding the foregoing, each Party shall have the right to make such disclosures as may be required by applicable laws, including applicable securities laws. Independent investigators that have been engaged by one or both parties shall be allowed to release information regarding studies performed by such investigators in a manner consistent with academic standards so long as each Party is given a reasonable opportunity to review such release of information to ensure that intellectual property being disclosed has been appropriately handled in accordance with Article 7, such review not to exceed [***] days.
